<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2401">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05129904</url>
  </required_header>
  <id_info>
    <org_study_id>NFEC-2021-259</org_study_id>
    <nct_id>NCT05129904</nct_id>
  </id_info>
  <brief_title>Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint (PADSTONE Study)</brief_title>
  <acronym>PADSTONE</acronym>
  <official_title>Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint: a Multicenter, Cluster-controlled Study (PADSTONE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Third Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing YouAn Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Kunming Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mengchao Hepatobiliary Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Ninth Hospital of Nanchang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Xinjiang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Shanxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shiyan Taihe Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Southwest Hospital of AMU</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Ditan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sichuan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People's Hospital of Guizhou Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LanZhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Ningxia Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute-on-chronic liver failure (ACLF) is life-threaten syndrome in patients with chronic&#xD;
      liver disease. In China, hepatitis B virus (HBV) is the main etiology of cirrhosis and&#xD;
      HBV-ACLF is characterized by multiple organs failure (liver, coagulation and kidney, etc.)&#xD;
      and associated with high risk of short-tern death. For the treatment of ACLF patients, recent&#xD;
      studies investigated the efficiency of extracorporeal liver support, such as albumin&#xD;
      dialysis, plasma exchange. However, the efficiencies remain unclear. Liver transplantation is&#xD;
      the most efficient way to improve the survival of ACLF patients, especially for those&#xD;
      patients with three or more organ failure.&#xD;
&#xD;
      More recently，an extracorporeal system which is called double plasma molecular absorption&#xD;
      system (DPMAS) was applied for the treatment of ACLF patients. DPMAS is an extracorporeal&#xD;
      procedure that combines two hemoperfusion machines. During the procedure, toxic plasma is&#xD;
      separated and cleansed by perfusion over two absorbers, and the final cleansed plasma is then&#xD;
      returned to patients. It does not require large volumes of plasma and nor does it bear the&#xD;
      risk of plasma-associated allergic reaction or disease transmissions. PMAS can attenuate the&#xD;
      jaundice in a short term and decrease the bilirubin concentration, which then reduces the&#xD;
      toxicities of bile acid and high levels of bilirubin on the hepatocytes. Although DPMAS&#xD;
      treatment is applied in the clinical practice for those patients with liver failure, it still&#xD;
      lack of compelling evidence in terms of real efficiency.&#xD;
&#xD;
      Thus, in this prospective, multicenter and cluster-controlled study, the investigators aim to&#xD;
      identify the optimal liver disease patients by using hard endpoints (short-term mortality and&#xD;
      disease progression). Moreover, this study will collect biological samples, including plasma,&#xD;
      urine and stool, to explore the precise profiling of ACLF patients with DPMAS therapy by&#xD;
      multi-omics detection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of progression with 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>The progression of ACLF with 4 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The 4-week transplant-free mortality</measure>
    <time_frame>4 weeks</time_frame>
    <description>The 4-week transplant-free mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The transplant-free mortality within 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>The transplant-free mortality within 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The improvement of ACLF with 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>The improvement of ACLF with 12 weeks</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>DPMAS Therapy in Liver Disease Patients</condition>
  <arm_group>
    <arm_group_label>Double plasma molecular absorption system treatment</arm_group_label>
    <description>Patients treat with DPMAS alone or in combination with plasma exchange</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard medical therapy</arm_group_label>
    <description>Patients with standard medical therapy except for DPMAS treatment or other artificial liver support system</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Double plasma molecular absorption system</intervention_name>
    <description>DPMAS is an extracorporeal procedure that combines two hemoperfusion machines. During the procedure, toxic plasma is separated and cleansed by perfusion over two absorbers, and the final cleansed plasma is then returned to patients. It does not require large volumes of plasma and nor does it bear the risk of plasma-associated allergic reaction or disease transmissions. DPMAS can attenuate the jaundice in a short term and decrease the bilirubin concentration, which then reduces the toxicities of bile acid and high levels of bilirubin on the hepatocytes</description>
    <arm_group_label>Double plasma molecular absorption system treatment</arm_group_label>
    <other_name>DPMAS treatment</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, urine，stool&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort 1:&#xD;
&#xD;
        Liver failure patients (Total bilirubin ≥ 12mg/dl and INR ≥ 1.5) treat with DPMAS alone or&#xD;
        in combination with plasma exchange&#xD;
&#xD;
        Cohort 2:&#xD;
&#xD;
        Liver failure patients (Total bilirubin ≥ 12mg/dl and INR ≥ 1.5) with standard medical&#xD;
        therapy except for DPMAS treatment or other artificial liver support system&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Hospitalized patients&#xD;
&#xD;
          2. Age &gt;18 years&#xD;
&#xD;
          3. Chronic liver disease regardless of the etiology&#xD;
&#xD;
          4. Total bilirubin ≥ 12mg/dl and INR ≥ 1.5&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Three or more organ failure (SOFA criteria)&#xD;
&#xD;
          2. Pregnant&#xD;
&#xD;
          3. With serve chronic non-liver organ failure&#xD;
&#xD;
          4. HIV infection without treatment&#xD;
&#xD;
          5. Unstable hemodynamics caused by acute bleeding&#xD;
&#xD;
          6. Proven infection with fever (&gt;37.5°C) or hemodynamically-instable&#xD;
&#xD;
          7. The diagnosis of hepatocellular carcinoma during screening period&#xD;
&#xD;
          8. Hospital stays &lt;48 hours&#xD;
&#xD;
          9. Patients unwilling to treat with DPMAS alone or in combination with plasma exchange&#xD;
             (suitable for the DPMAS treatment group)&#xD;
&#xD;
         10. Patients with DPMAS treatment or other artificial liver support system (suitable for&#xD;
             Standard medical therapy group)&#xD;
&#xD;
         11. Not sign the informed consent&#xD;
&#xD;
         12. Not suitable to participate in this study judging by the researchers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinjun Chen, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Nanfang Hospital, Sourthern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinjun Chen, Doctor</last_name>
    <phone>18588531001</phone>
    <email>chjj@smu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beiling Li</last_name>
    <phone>13570541527</phone>
    <email>820584791@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinjun Chen</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 31, 2021</study_first_submitted>
  <study_first_submitted_qc>November 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Jinjun Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>double plasma molecular absorption system</keyword>
  <keyword>liver disease</keyword>
  <keyword>acute-on-chronic liver failure</keyword>
  <keyword>mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

